Aim To analyse large‐scale cardiovascular outcome trials of sodium‐glucose co‐transporter‐
2 (SGLT‐2) inhibitors to evaluate whether there are safety concerns with respect to major …

Background Concerns have been raised on the risk of lower limb amputations with SGLT-2
inhibitors. Aim of the present metanalysis is the assessment of the effect of SGLT-2inhibitors …

Background The association between sodium-glucose cotransporter 2 inhibitors (SGLT2i's)
and lower extremity amputation is unclear. Purpose To systematically review randomized …

Aim To examine whether sodium‐glucose co‐transporter‐2 (SGLT2) inhibitors are
associated with a higher risk of lower‐extremity amputation than dipeptidyl‐peptidase‐4 …

Inhibitors of the sodium‐glucose co‐transporter‐2 (SGLT‐2) are a novel class of glucose‐
lowering agents that show promising results. However, the use of canagliflozin has been …

Background To exam the associations between the use of sodium glucose co-transporter 2
inhibitor (SGLT2i) and the risk of lower limb complications, and to analyze the associated …

Aim To determine the risk of amputations associated with sodium‐glucose co‐transporter‐2
inhibitors (SGLT2i) relative to dipeptidyl peptidase‐4 inhibitors (DPP4i). Materials and …

Abstract Sodium‐glucose co‐transporter‐2 (SGLT2) inhibitors prevent cardiovascular
complications in type 2 diabetes. We aimed to study whether they have similar effects in …

Abstract Sodium-glucose co-transporter-2 inhibitors (SGLT2i) are oral antidiabetic agents
that exert their glucose-lowering effect by increasing renal excretion of glucose. These drugs …

Aim Sodium glucose co-transporter 2 (SGLT2) inhibitors appear to protect against increased
risks of cardiovascular and kidney disease in patients with type 2 diabetes but also cause …